Insider trade

Lyell Immunopharma (LYEL): Director bought ~$20K

Otis W Brawley, Director at Lyell Immunopharma, bought ~$20K of Lyell Immunopharma shares.

~$20K
Approx. value · 36K sh @ $0.56
36K
Holds after · shares reported
Traded
Mar 31, 2025
Filed
Apr 2, 2025

What stands out in this filing

  • After this purchase the filing reports 35,640 shares.
  • 35,640 shares at an average of $0.56 each, as reported on the form.
  • 4 other insiders at LYEL also bought in the open market within 30 days.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 14, 2025Insider · 2 peopleInsiders: 2 purchases (~$201K)
  2. Mar 17, 2025InsiderCFO purchased ~$112K of LYEL shares in the open market
  3. Mar 21, 2025InsiderDirector purchased ~$115K of LYEL shares in the open market
  4. Mar 31, 2025 · this disclosureInsiderDirector purchased ~$20K of LYEL shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Lyell Immunopharma

For Lyell Immunopharma, OQRO holds 7 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LYEL page.

How this filing works

Explore the data

Common questions

Which Lyell Immunopharma (LYEL) insider traded, and how much?

Otis W Brawley, Director at Lyell Immunopharma, bought ~$20K of Lyell Immunopharma shares. 36K shares at $0.56, open market.

When did it happen, and when was it made public?

Traded: Mar 31, 2025. Filed: Apr 2, 2025. That is 2 days between the two dates.

What stands out in this filing?

After this purchase the filing reports 35,640 shares. 35,640 shares at an average of $0.56 each, as reported on the form. 4 other insiders at LYEL also bought in the open market within 30 days.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Lyell Immunopharma recently?

For Lyell Immunopharma, OQRO holds 7 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the LYEL page.

Does this mean LYEL stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Lyell Immunopharma

Everything OQRO holds on this company is on its LYEL page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data